Share
.webp)
.webp)
.webp)
.webp)
Daniel Lochner
Tectonic Therapeutic, Inc. has announced the appointment of Daniel Lochner as its new Chief Financial Officer.
“Dan is a highly experienced public-company CFO with a deep understanding of the healthcare and biopharmaceutical sectors,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. “We are excited to welcome him to the team, where his financial expertise will be invaluable as we continue advancing our mission.”
Mr. Lochner brings nearly 15 years of healthcare equity investing experience and a strong background in corporate finance, business strategy, and operations. Before joining Tectonic, he served as Chief Business Officer and Chief Financial Officer of Viatris' Eye Care Division, following the acquisition of Oyster Point Pharma, where he held similar roles. His leadership was instrumental in driving business strategy and executing operational goals at Oyster Point Pharma. Previously, Mr. Lochner was a Managing Director and Equity Portfolio Manager at Goldman Sachs, where he invested in biotechnology, pharmaceuticals, and healthcare services. He holds an MBA from Columbia University and a BA in Economics from the University of Richmond.
"It’s an exciting time to join Tectonic, a company at the cutting edge of scientific innovation," said Mr. Lochner. "I look forward to contributing to the development of GPCR-targeted biologic therapies and advancing the company’s mission."
Christian Cortis, Ph.D., who currently serves as both Chief Operating Officer and Chief Financial Officer, will be departing the company to pursue external opportunities. He will assist in the transition through early July and continue as a strategic advisor thereafter. Dr. Reicin expressed her gratitude for Dr. Cortis' contributions, particularly his role in the company's growth and its upcoming merger with AVROBIO.
